ERIS Lifesciences Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹807Cr
- +11% YoY
- +1.9% QoQ
- Net profit
- ₹109Cr
- +25.3% YoY
- −18.7% QoQ
- Margin
- 35%
- +1 pp YoY
- −1 pp QoQ
Guidance rank: #50 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
Domestic Branded Formulations (DBF) business expects 12% revenue growth for FY26, with Q3 showing 10% growth and 13-14% growth expected for the full year excluding non-core brands. Eris Lifesciences forecasts 12% revenue growth in Domestic Branded Formulations (DBF) for FY26 with a 37% operating margin.
From ERIS Lifesciences Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Domestic Branded Formulations (DBF) business expects 12% revenue growth for FY26, with Q3 showing 10% growth and 13-14% growth expected for the full year excluding non-core brands.
- DBF segment targets a 37% operating margin this year and 39%+ EBITDA margin next year.
- Significant market share gains in the RHI insulin cartridge segment: from 8% at acquisition to 25-26% by Dec-Jan, with further growth expected in the RHI plus Glargine segment over the next 3 years.
- International business delivered 45% revenue growth in Q3, with strong visibility for FY27 revenue between INR 550-600 crores.
- CDMO revenue expected to grow, with INR 125-160 crore anticipated next year and full commercialization of a INR 1,000 crore order book over three years.
- Launch of GLP-1 products (Semaglutide) expected to drive growth, with initial margin pressure but overall positive top-line impact.
2 more points from ERIS Lifesciences Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what ERIS Lifesciences Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Ongoing capital investments are focused on Injectables, Insulin, Monoclonal Antibodies (MABs), and GLP-1 segments, continuing as per guidance (Page 16).
- CapEx for FY26 Q3 was about INR 80 crore, with nine-month CapEx around INR 200 crore, targeting Insulin, GLP-1, and Injectable projects (Page 5).
- The 3-year CapEx guidance remains around INR 200-250 crore per annum, totaling approximately INR 750 crore for FY26-FY28 (Pages 5 and 6).
- Investment front-loaded to capitalize on strategic opportunities in Injectable Insulin and GLP segments (Page 6).
2 more points from ERIS Lifesciences Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what ERIS Lifesciences Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The current CDMO order book stands at an annualized size of INR 1,000 crore as of Q3FY26.
- This INR 1,000 crore order book is additional to the existing base business, primarily from the Swiss facility.
- The full commercialization and execution of this INR 1,000 crore order book is expected to take about three years.
- For the next year (FY27), the company expects CDMO revenues of INR 125-160 crore.
- The company has strong visibility of FY27 as a breakout year for international revenues, targeting INR 550-600 crore.
2 more points from ERIS Lifesciences Ltd's call on order book
Create a free account to keep reading this call
ERIS Lifesciences Ltd — Quarterly revenue & net profit
ERIS Lifesciences Ltd Q3 FY26 results — key figures
| ₹ Cr | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 807 | 727 | +11% | 792 | +1.9% |
| Operating profit (EBITDA) | 282 | 250 | +12.8% | 288 | -2.1% |
| Operating margin | 35% | 34% | +1 pp | 36% | -1 pp |
| Profit before tax | 145 | 116 | +25% | 173 | -16.2% |
| Net profit (PAT) | 109 | 87 | +25.3% | 134 | -18.7% |
| EPS (₹) | 7.32 | 6.15 | +19% | 8.82 | -17% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹892 Cr, net profit ₹187 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What ERIS Lifescience's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
ERIS Lifesciences Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were ERIS Lifesciences Ltd Q3 FY26 results?
Domestic Branded Formulations (DBF) business expects 12% revenue growth for FY26, with Q3 showing 10% growth and 13-14% growth expected for the full year excluding non-core brands. Eris Lifesciences forecasts 12% revenue growth in Domestic Branded Formulations (DBF) for FY26 with a 37% operating margin.
What is ERIS Lifesciences Ltd share price analysis?
ERIS Lifesciences Ltd currently shows a neutral. The stock trades at a P/E of 29.1 with a market cap of ₹19,057 Cr. Investors should review the full earnings analysis for detailed insights.
Is ERIS Lifesciences Ltd planning capital expenditure?
Ongoing capital investments are focused on Injectables, Insulin, Monoclonal Antibodies (MABs), and GLP-1 segments, continuing as per guidance (Page 16).
Keep ERIS Lifesciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
